Oragenics Inc.
As of Oct 22, 2026, Oragenics is in Stage 4, the downtrend phase, now in week 46 (since Nov 25, 2025). It closed at $0.41, 69.2% below its 52-week high and below its 200-day average, which is falling.
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is OGEN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
OGEN among Biotechnology423rd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …423 | OGEN | Stage 4 · wk 46 | 15 | −16.3% |
Oragenics: quick answers
What stage is Oragenics in?
As of Oct 22, 2026, Oragenics (OGEN) is in Stage 4, the downtrend phase. It entered Stage 4 on Nov 25, 2025 and is in week 46. What the four stages mean
Is Oragenics in an uptrend?
No. Oragenics is in a Stage 4 downtrend. It trades 34.1% below its 200-day average, which is falling.
How far is Oragenics from its 52-week high?
Oragenics closed at $0.41 on Oct 22, 2026, 69.2% below its 52-week high of $1.33. Its 52-week low is $0.41.
How has Oragenics performed over the past year?
As of Oct 22, 2026, Oragenics is down 70.1% over the past year and down 51.2% so far in 2026.
Which sector and industry is Oragenics in?
Oragenics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.